PolyMedix, Inc, has received a Phase 2 grant in the amount of $986,000 from the National Institute of Health (NIH) to support the development of defensin mimetic antimicrobial compounds for the treatment of oral candidiasis.
Read MoreThe initial phase of this grant provides PolyMedix with $0.5 million over the first year, with the opportunity for an additional $0.5 million in the second year, to validate and pursue defensin-mimetic antimicrobial compounds.
Read More